Athena Bioscience, LLC ta sanar da tsare-tsare don ƙaddamar da kasuwanci na Nexiclon XR, allunan ƙarar sakin clonidine sau ɗaya kowace rana da aka nuna don maganin hauhawar jini.1 Athena ta sami keɓantaccen haƙƙoƙi don tallata samfurin daga Tris Pharma, Inc. a cikin Fabrairu 2021. an saita ƙaddamarwa don Afrilu 2022 a duk jihohin Amurka 50.

A matsakaita, kawai 50% na manya suna bin magungunan cututtuka na yau da kullun2, kuma a cikin yanayin cutar hawan jini (BP), ƙananan matakan haɗin gwiwa suna da alaƙa da mafi munin sarrafa BP da sakamako mara kyau, ciki har da bugun jini, bugun jini na zuciya, gazawar zuciya, da rashin ƙarfi. mutuwa.3-5 Nexiclon XR yana ba da fa'idodin asibiti na antihypertensive iri ɗaya na clonidine da aka saki nan da nan a cikin kwamfutar hannu mai dacewa, sau ɗaya kowace rana.6.

"Mun yi imanin dacewa da kwamfutar hannu sau ɗaya kowace rana na iya ba da gudummawa ga karuwar masu haƙuri ga tsarin magunguna," in ji Jeff Bryant, Shugaba na Athena. "Mafi kyawun yarda ya kamata ya samar da ingantattun sakamako na warkewa ga waɗanda ke fama da hauhawar jini."

"Kaddamar da Nexiclon XR ya nuna nasarar da Tris ya ci gaba da kawo bambance-bambancen magungunan fasaha a kasuwa," in ji Shugaba Tris Ketan Mehta. "Idan aka yi la'akari da ingantaccen tarihin su, muna farin ciki cewa Athena abokin aikinmu ne, wanda ya ƙaddamar da wannan muhimmin samfurin na zuciya." Nexiclon ya dogara ne akan fasahar isar da magunguna na Tris's LiquiXR®, wanda ya haifar da haɓaka samfuran farko-in-categories da yawa.

ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:

On average, only 50% of adults adhere to chronic disease medications2, and in the case of high blood pressure (BP), lower levels of adherence are associated with worse BP control and adverse outcomes, including stroke, myocardial infarction, heart failure, and death.
“We believe the convenience of a once-daily tablet can contribute to increased patient adherence to medication regimens,”.
The launch is set for April 2022 in all 50 U.